Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus Nab-Paclitaxel for Metastatic Breast Cancer-In Reply.
作者信息
Adams Sylvia, Molinero Luciana
机构信息
New York University Perlmutter Cancer Center, New York, New York.
Oncology Biomarkers Development, Genentech Inc, South San Francisco, California.
出版信息
JAMA Oncol. 2019 Jun 1;5(6):908-909. doi: 10.1001/jamaoncol.2019.0317.
PMID:30998805
Abstract
摘要
相似文献
1
Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus Nab-Paclitaxel for Metastatic Breast Cancer-In Reply.关于阿替利珠单抗联合白蛋白结合型紫杉醇用于转移性乳腺癌的1b期临床试验的相关问题——回复
JAMA Oncol. 2019 Jun 1;5(6):908-909. doi: 10.1001/jamaoncol.2019.0317.
2
Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus nab-Paclitaxel for Metastatic Breast Cancer.关于阿替利珠单抗联合白蛋白结合型紫杉醇用于转移性乳腺癌的1b期临床试验的担忧
JAMA Oncol. 2019 Jun 1;5(6):908. doi: 10.1001/jamaoncol.2019.0314.
3
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
4
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿特珠单抗与白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌
N Engl J Med. 2019 Mar 7;380(10):986. doi: 10.1056/NEJMc1900150.
5
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗与白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌
N Engl J Med. 2019 Mar 7;380(10):986-987. doi: 10.1056/NEJMc1900150.
6
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.阿特珠单抗和白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌。回复。
N Engl J Med. 2019 Mar 7;380(10):987-988. doi: 10.1056/NEJMc1900150.
7
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.阿替利珠单抗联合白蛋白紫杉醇治疗PD-L1阳性三阴性乳腺癌——信函
Clin Cancer Res. 2020 Jul 15;26(14):3892-3893. doi: 10.1158/1078-0432.CCR-20-0668.
8
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.一项在 HER2 阳性早期乳腺癌患者中应用辅助纳米白蛋白结合紫杉醇和环磷酰胺联合曲妥珠单抗治疗的初步研究。
Breast Cancer Res Treat. 2010 Sep;123(2):471-5. doi: 10.1007/s10549-010-1047-0. Epub 2010 Jul 24.
9
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗与白蛋白结合型紫杉醇治疗晚期三阴性乳腺癌
N Engl J Med. 2019 Mar 7;380(10):985-986. doi: 10.1056/NEJMc1900150.
10
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.白蛋白结合型紫杉醇联合生物靶向药物治疗早期和转移性乳腺癌。
Cancer Treat Rev. 2014 Jun;40(5):614-25. doi: 10.1016/j.ctrv.2014.02.001. Epub 2014 Feb 12.
Zotero 插件